Science & Technology
Science and Technology
Science and Technology
Mon, January 19, 2009
Sat, January 17, 2009
Fri, January 16, 2009 Diamond Reference Laboratory Signs Agreement to Upgrade Aspyra LIS and Implement Anatomic Pathology Module
CALABASAS, Calif.--([ BUSINESS WIRE ])--Aspyra, Inc. (AMEX: APY) announced today that the Company has entered into an agreement with Diamond Reference Laboratory (DRL), an independent clinical reference laboratory in Diamond Bar, California to upgrade the laboratory's existing LIS to the most current release of Aspyra's CyberLAB® Laboratory Information System (LIS) solution, version 7.2, as well as implement the Company's CyberPATH® Anatomic Pathology module.
DRL has been an Aspyra LIS customer since 1989. The full-service, CLIA accredited laboratory currently serves the southern California area, distributing clinical results electronically to its growing client base.
Abbas Rajaee, owner of Diamond Reference Laboratory stated, "In today's changing economy and tough competitive market, laboratories are hard pressed to maintain their current market with the changes in the health environment through collaboration and with the teamwork of our clients. For over 20 years, Aspyra has provided us the tools sets and service we need to remain competitive. We look forward to using the new version of CyberLAB to further advance our services."
"DRL provides added service to its clients by enabling access and quick turnaround of clinical results electronically, when and how they need them. In addition to the automated report distribution module within CyberLAB, DRL also has patient result data transmit from the LIS to their client's third party practice management systems," stated Michelle Del Guercio, Aspyra's Director of Marketing and Product Management. She continued, "DRL will continue to improve workflow efficiencies with the latest release of CyberLAB 7.2, with features such as advanced automated result processing functions, which also reduce human error and improve turnaround."
DRL has also purchased the Aspyra CyberPATH Anatomic Pathology module, to automate the pathology and cytology workflow and reporting within the laboratory. Aspyra's CyberLAB® LIS system is a scalable, feature-rich, and proven LIS solution for the hospital, clinic, and reference laboratory settings. CyberLABLIS features decision support tools with auto-verification, automated clinical reporting and multisite management.
About Aspyra
Aspyra is a global provider of Health Care Information Technology (HCIT) solutions and services to the healthcare industry. The Company specializes in Clinical Information Systems (CIS), Picture Archive Communication Systems (PACS) and Clinical Image Management Systems (CIMS) for hospitals, multi-specialty clinics, clinical laboratories, imaging departments and centers and orthopedic environments. Aspyra's highly scalable systems can be installed standalone or integrated to provide a single-vendor, enterprise-wide solution. For more information on Aspyra, its products and services, visit [ www.aspyra.com ].
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and are inherently subject to uncertainties and other factors which could cause actual results to differ materially from the forward-looking statement. Such statements are based upon, among other things, assumptions made by, and information currently available to, management as of the date of this release, including management's own knowledge and assessment of the Company's industry, customers and competition. Factors that could cause Aspyra's actual results to differ materially from these forward-looking statements include among others: changes in the Company's management or other personnel, the competitive environment for Company products and services; unexpected technical and marketing difficulties inherent in major product development efforts; the potential need for changes in the Company's long-term strategy in response to future developments; future advances in clinical information technology and procedures, as well as potential changes in government regulations and healthcare policies; and rapid technological change in the microelectronics and software industries. The Company refers interested persons to its most recent Annual Report on Form 10-KSB and its other SEC filings for a description of additional uncertainties and factors, which may affect forward-looking statements. The Company assumes no duty to update its forward-looking statements.
